These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 20053761)
1. Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201). El-Sahwi K; Bellone S; Cocco E; Casagrande F; Bellone M; Abu-Khalaf M; Buza N; Tavassoli FA; Hui P; Rüttinger D; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD Mol Cancer Ther; 2010 Jan; 9(1):57-66. PubMed ID: 20053761 [TBL] [Abstract][Full Text] [Related]
2. Primary cervical carcinoma cell lines overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody. Richter CE; Cocco E; Bellone S; Bellone M; Casagrande F; Todeschini P; Rüttinger D; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD Int J Gynecol Cancer; 2010 Dec; 20(9):1440-7. PubMed ID: 21370592 [TBL] [Abstract][Full Text] [Related]
3. Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody. Varughese J; Cocco E; Bellone S; de Leon M; Bellone M; Todeschini P; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD Cancer; 2011 Jul; 117(14):3163-72. PubMed ID: 21246534 [TBL] [Abstract][Full Text] [Related]
4. High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody. Richter CE; Cocco E; Bellone S; Silasi DA; Rüttinger D; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD Am J Obstet Gynecol; 2010 Dec; 203(6):582.e1-7. PubMed ID: 20870202 [TBL] [Abstract][Full Text] [Related]
5. Overexpression of HER-2/neu in uterine serous papillary cancer. Santin AD; Bellone S; Gokden M; Palmieri M; Dunn D; Agha J; Roman JJ; Hutchins L; Pecorelli S; O'Brien T; Cannon MJ; Parham GP Clin Cancer Res; 2002 May; 8(5):1271-9. PubMed ID: 12006548 [TBL] [Abstract][Full Text] [Related]
6. hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma. Cocco E; Hu Z; Richter CE; Bellone S; Casagrande F; Bellone M; Todeschini P; Krikun G; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Buza N; Pecorelli S; Lockwood CJ; Santin AD Br J Cancer; 2010 Sep; 103(6):812-9. PubMed ID: 20700124 [TBL] [Abstract][Full Text] [Related]
7. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro. Bellone S; Black J; English DP; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Ferrari F; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD Am J Obstet Gynecol; 2016 Jan; 214(1):99.e1-8. PubMed ID: 26272866 [TBL] [Abstract][Full Text] [Related]
8. In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma. El-Sahwi K; Bellone S; Cocco E; Cargnelutti M; Casagrande F; Bellone M; Abu-Khalaf M; Buza N; Tavassoli FA; Hui P; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD Br J Cancer; 2010 Jan; 102(1):134-43. PubMed ID: 19920829 [TBL] [Abstract][Full Text] [Related]
9. High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody. Varughese J; Cocco E; Bellone S; Bellone M; Todeschini P; Carrara L; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD Gynecol Oncol; 2011 Jul; 122(1):171-7. PubMed ID: 21453957 [TBL] [Abstract][Full Text] [Related]
10. Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy. Bellone S; Siegel ER; Cocco E; Cargnelutti M; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD Int J Gynecol Cancer; 2009 Jul; 19(5):860-6. PubMed ID: 19574774 [TBL] [Abstract][Full Text] [Related]
11. Expression of αV-integrins in uterine serous papillary carcinomas; implications for targeted therapy with intetumumab (CNTO 95), a fully human antagonist anti-αV-integrin antibody. Bellone M; Cocco E; Varughese J; Bellone S; Todeschini P; El-Sahwi K; Carrara L; Guzzo F; Schwartz PE; Rutherford TJ; Pecorelli S; Marshall DJ; Santin AD Int J Gynecol Cancer; 2011 Aug; 21(6):1084-90. PubMed ID: 21633302 [TBL] [Abstract][Full Text] [Related]
12. Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer. Cocco E; Bellone S; El-Sahwi K; Cargnelutti M; Casagrande F; Buza N; Tavassoli FA; Siegel ER; Visintin I; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD Br J Cancer; 2009 Jul; 101(2):335-41. PubMed ID: 19536090 [TBL] [Abstract][Full Text] [Related]
13. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro. Ferrari F; Bellone S; Black J; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Menderes G; Litkouhi B; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD J Exp Clin Cancer Res; 2015 Oct; 34():123. PubMed ID: 26474755 [TBL] [Abstract][Full Text] [Related]
14. Overexpression of claudin-3 and claudin-4 receptors in uterine serous papillary carcinoma: novel targets for a type-specific therapy using Clostridium perfringens enterotoxin (CPE). Santin AD; Bellone S; Marizzoni M; Palmieri M; Siegel ER; McKenney JK; Hennings L; Comper F; Bandiera E; Pecorelli S Cancer; 2007 Apr; 109(7):1312-22. PubMed ID: 17326053 [TBL] [Abstract][Full Text] [Related]
15. Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer. Santin AD; Diamandis EP; Bellone S; Soosaipillai A; Cane S; Palmieri M; Burnett A; Roman JJ; Pecorelli S Clin Cancer Res; 2005 May; 11(9):3320-5. PubMed ID: 15867230 [TBL] [Abstract][Full Text] [Related]
16. Trop-2 overexpression in poorly differentiated endometrial endometrioid carcinoma: implications for immunotherapy with hRS7, a humanized anti-trop-2 monoclonal antibody. Bignotti E; Ravaggi A; Romani C; Falchetti M; Lonardi S; Facchetti F; Pecorelli S; Varughese J; Cocco E; Bellone S; Schwartz PE; Rutherford TJ; Santin AD Int J Gynecol Cancer; 2011 Dec; 21(9):1613-21. PubMed ID: 21892093 [TBL] [Abstract][Full Text] [Related]
17. Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody. Varughese J; Cocco E; Bellone S; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Buza N; Pecorelli S; Santin AD Am J Obstet Gynecol; 2011 Dec; 205(6):567.e1-7. PubMed ID: 21889762 [TBL] [Abstract][Full Text] [Related]
18. An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer. Schmidt M; Scheulen ME; Dittrich C; Obrist P; Marschner N; Dirix L; Schmidt M; Rüttinger D; Schuler M; Reinhardt C; Awada A Ann Oncol; 2010 Feb; 21(2):275-282. PubMed ID: 19633042 [TBL] [Abstract][Full Text] [Related]
19. Higher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro. Paik D; Cocco E; Bellone S; Casagrande F; Bellone M; Siegel EE; Richter CE; Schwartz PE; Rutherford TJ; Santin AD Gynecol Oncol; 2010 Oct; 119(1):140-5. PubMed ID: 20673976 [TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma. Han C; Perrone E; Zeybek B; Bellone S; Tymon-Rosario J; Altwerger G; Menderes G; Feinberg J; Haines K; Muller Karger ME; Bianchi A; Zammataro L; Manzano A; Bonazzoli E; Manara P; Buza N; Hui P; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Lopez S; Santin AD Gynecol Oncol; 2020 Feb; 156(2):430-438. PubMed ID: 31839338 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]